Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop.

Gupta M, Choudhury PS, Rawal S, Goel HC, Talwar V, Singh A, Sahoo SK.

World J Nucl Med. 2018 Oct-Dec;17(4):261-269. doi: 10.4103/wjnm.WJNM_79_17.

2.

Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: A one-stop-shop.

Gupta M, Choudhury PS, Rawal S, Goel HC, Singh A, Talwar V, Sahoo SK.

Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:156.

PMID:
29324926
4.

Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.

BJU Int. 2017 Feb;119(2):209-215. doi: 10.1111/bju.13540. Epub 2016 Jun 18.

5.

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.

Eur Urol. 2016 Oct;70(4):553-557. doi: 10.1016/j.eururo.2015.12.051. Epub 2016 Jan 19.

PMID:
26810345
6.

Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C.

Eur Urol. 2016 Mar;69(3):393-6. doi: 10.1016/j.eururo.2015.06.010. Epub 2015 Jun 25.

PMID:
26116958
7.

Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.

Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.

J Transl Med. 2017 Nov 7;15(1):230. doi: 10.1186/s12967-017-1333-2.

8.

Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R.

Urology. 2017 Aug;106:139-145. doi: 10.1016/j.urology.2017.04.019. Epub 2017 Apr 21.

PMID:
28438628
9.

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.

J Urol. 2016 May;195(5):1436-1443. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.

PMID:
26682756
10.

68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.

Zang S, Shao G, Cui C, Li TN, Huang Y, Yao X, Fan Q, Chen Z, Du J, Jia R, Sun H, Hua Z, Tang J, Wang F.

Oncotarget. 2017 Feb 14;8(7):12247-12258. doi: 10.18632/oncotarget.14691.

11.

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.

BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x. Epub 2012 Apr 23.

13.

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.

Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.

Radiat Oncol. 2017 Nov 10;12(1):176. doi: 10.1186/s13014-017-0902-0.

14.

Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.

Prostate. 2015 Dec;75(16):1934-40. doi: 10.1002/pros.23091. Epub 2015 Sep 10.

PMID:
26356236
15.

Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.

Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C.

Nucl Med Commun. 2017 Dec;38(12):1094-1102. doi: 10.1097/MNM.0000000000000749.

PMID:
28957842
16.

[11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy.

Schumacher MC, Radecka E, Hellström M, Jacobsson H, Sundin A.

Scand J Urol. 2015 Feb;49(1):35-42. doi: 10.3109/21681805.2014.932840. Epub 2014 Jul 8.

PMID:
25001948
17.

The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.

Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, Yücetaş U, Demirdağ Ç, Erdoğan SM, Kabasakal L; Members of Urooncology Association, Turkey.

Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1806-1812. doi: 10.1007/s00259-017-3752-y. Epub 2017 Jun 18.

PMID:
28624849
18.

68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.

Udovicich C, Perera M, Hofman MS, Siva S, Del Rio A, Murphy DG, Lawrentschuk N.

Prostate Int. 2017 Dec;5(4):125-129. doi: 10.1016/j.prnil.2017.02.003. Epub 2017 Feb 24. Review.

19.

Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.

Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, Oyen R, Ameye F, Bogaerts K, Haustermans K, Van Poppel H.

Eur Urol. 2011 Jul;60(1):125-30. doi: 10.1016/j.eururo.2011.01.015. Epub 2011 Jan 18.

PMID:
21292388
20.

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.

Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.

BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3.

PMID:
29726071

Supplemental Content

Support Center